Related Experiment Video
Updated: Jul 31, 2025
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
Published on: November 29, 2019
Cerebrospinal fluid B-cell activating factor levels as a novel biomarker in patients with neurosarcoidosis
Kaori Sumi1, Teruaki Masuda1, Noriyuki Kimura1
1Department of Neurology, Faculty of Medicine, Oita University, Oita, Japan.
Objectives:
Neurosarcoidosis (NS) is a severe complication of sarcoidosis. Patients with NS often have poor outcomes. To improve both the quality of life and prognosis in patients with NS, accurate and reliable methods for early diagnosis and determining the efficacy of treatment are needed. This study aims to investigate B-cell-activating factor of the tumor necrosis factor family (BAFF) in cerebrospinal fluid (CSF) and elucidate the relationship between CSF BAFF levels and various parameters of NS.
Methods:
We studied 20 patients with NS and 14 control subjects. We measured CSF BAFF levels in all subjects and investigated the relationship with clinical findings, serum and CSF measures, and magnetic resonance imaging (MRI) findings.
Results:
CSF BAFF levels were significantly increased in patients with NS compared with controls (median 0.089 vs 0.04 ng/mL, p = 0.0005). CSF BAFF values were correlated with CSF findings-cell count, protein, angiotensin-converting enzyme, lysozyme, soluble interleukin-2 receptor, and immunoglobulin G-but not with serum parameters. CSF BAFF levels were especially higher in patients with abnormal intraparenchymal lesions of the brain and abnormal spinal MRI findings. CSF BAFF levels decreased significantly after immunosuppressive therapy.
Conclusion:
CSF BAFF may aid the quantitative evaluation of NS and may serve as a biomarker for this disease.
